HBM Holdings Limited (2142.HK) HKSE
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
HBM Holdings Limited
Sector
Healthcare
Industry
Biotechnology
Employees
327
First IPO Date
December 10, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Jingsong Wang | Founder, Chairman & Chief Executive Officer | 8.67M | 1965 |
| Yiping Rong | Chief Scientific Officer & Executive Director | 3.33M | 1977 |
| Bob Zhang | President of Metabolic Disease Franchise | 0 | N/A |
| Steve Arkinstall DPhil | Chief Scientific Advisor | 0 | N/A |
| Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | 0 | N/A |
| Wing Yat Lui | Joint Company Secretary | 0 | 1989 |
| Youchen Chen | VP, CFO, Executive Director & Investor Relations | 0 | N/A |
| C. Adam Zong | President | 0 | N/A |
| Ian Y. Liu | Senior VP & Global Head of Legal, Joint Company Secretary, Executive Director | 0 | N/A |
| Jenny Xie | Chief Scientific Officer for Immunology & Head of Global External Innovation | 0 | N/A |
| Peter F. Moesta | Member of Scientific Advisory Board & Chief CMC Advisor | 0 | N/A |
| Raymond S. Zheng | Chief Business Officer | 0 | N/A |
Description
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
